ECE2017 Guided Posters Diabetes therapy & complications 2 (10 abstracts)
Hepatic effects of GLP-1 receptor agonist Liraglutide in patients with type 2 diabetes
Maria Hayon 1 , Marta Fernandez 1 , Silvia Maraver 2 , Teresa Muros 1 , Daniel Cepero 3 , Martin Lopez 1 , Miguel Quesada 1 , Joaquin Pechuan 4 & Gonzalo Piedrola 1
1Complejo Hospitalario Universitario de Granada, Granada, Spain; 2Clínico Virgen de la Victoria Hospital, Malaga, Spain; 3Torrecardenas Hospital, Almeria, Spain; 4Endocrinology Private Office, Granada, Spain.
Introduction: The aim of this study was to analyze the effects of Liraglutide in hepatic steatosis as well as clinical and biochemical data before and after 6 months.
Methods: We have retrospectively analysed epidemiological, anthropometric and laboratory data of 83 type 2 diabetic patients treated with Liraglutide and followed at different endocrinology units across east Andalusia. We have evaluated nonalcoholic fatty liver disease using liver enzymes and hepatic steatosis index (HSI). HSI>36 reflects fatty liver, <30 absence, and intermediate values are considered indeterminated.
Results: Of the 83 cases evaluated, 54.2% were male, mean age 56.76±9.87 years, time from diagnosis 9.46±5.46 years. Prior to treatment, patients had BMI 37.68±6.82 kg/m2, blood pressure 138.80/82.87 mmHg, fasting glucose 187.33±55.11 mg/dl, glycated hemoglobin (HbA1C) 8.62±1.3%, total cholesterol 178.1±35.74 mg/dl (c-LDL 97.66±32.16 mg/dl, c-HDL 44.54±13.78 mg/dl), triglycerides 197.64±24.19 mg/dl, AST 29±20.311 U/l, ALT 39.88±31.69 U/l and HSI 46.44±6.48.
Clinical and biochemical figures at 6 months were: BMI 36.08±6.32 kg/m2, blood pressure 132.76/77.41 mmHg, fasting glucose 165.16±56 mg/dl, HbA1C 7.73±1.33%, total cholesterol 170.6±39.19 mg/dl (c-HDL 46.25±15.03 mg/dl, c-LDL 87.74±30.5 mg/dl), triglycerides 198.29±22.29 mg/dl, AST 24.97±12.49 U/l, ALT 32.76±18.24 U/l, and HSI 43.98±6.38.
Statistically significant differences were found regarding several variables, such as BMI, HbA1C, fasting glucose, blood pressure and c- LDL, as well as in ALT and HSI, showing an amelioration in hepatic steatosis. No differences were found in total cholesterol, c-HDL, triglycerides and AST.
Conclusion: In our study, six- month therapy with Liraglutide improves, not only risk factors for cardiovascular disease, but also hepatic steatosis as shown by a decrease in HSI index and ALT.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more